GCAR Announces Evaluation of AZD1390 in GBM AGILE Trial

November 22, 2024  |  PRNewswire

GCAR and Polaris Launch ADI-PEG 20 in GBM AGILE Trial

August 15, 2023  |  BUSINESSWIRE

GBM AGILE Opens to Paxalisib in Europe

May 31, 2022  |  KAZIA THERAPEUTICS

GBM AGILE Opens to Paxalisib in Canada

November 29, 2021  |  KAZIA THERAPEUTICS

GCAR Launches Ovarian CanceRx for Advanced Cancer Therapies

September 23, 2021  |  BUSINESSWIRE

Kazia Executes Agreement to Commence GBM AGILE Pivotal Study

October 16, 2020  |  KAZIA THERAPEUTICS

GCAR Appoints Jeffrey Tarrant to Board of Directors

June 13, 2019  |  BUSINESSWIRE

GCAR Names Meredith Buxton Chief Operating Officer

January 31, 2019  |  GLOBAL COALITION FOR ADAPTIVE RESEARCH

Bayer’s Regorafenib is the First Drug to Enter GBM AGILE

November 14, 2018  |  BUSINESSWIRE

4 Ways Cancer is Changing How We Test Medicines

October 18, 2018  |  POLITICO